Ryan G. Kruger

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T. McCabe, Heidi M. Ott, Gopinath Ganji et al. · Nature · 2012 · 1.8K citations

Ezh2 Inhibition, Lymphoid Neoplasia, Hematological Malignancy +10

The promise and peril of chemical probes

C.H. Arrowsmith, James E. Audia, Christopher P. Austin et al. · Nature Chemical Biology · 2015 · 836 citations · Full text

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

Wendy Béguelin, Relja Popovic, Matt Teater et al. · Cancer Cell · 2013 · 828 citations · Full text

Chromatin, Developmental Biology, Germ Cell +9

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 533 citations

Vitro Potency, Signal Transduction, Medicine +10

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 498 citations · Full text

Oncogenic Agent, Medicine, Epigenetic Change +9